Fig. 2: Microbiological characterization of MK-7762.

a, MIC₉₉ for linezolid and MK-7762 against a globally diverse collection of drug-susceptible (DS) and drug-resistant (MDR and XDR, referring to strains with increasing levels of drug resistance). (Drug susceptibility testing (DST) from clinical testing against the following drugs; H, isoniazid; R, rifampicin; E, ethambutol; S, streptomycin; K, kanamycin; P, p-aminosalicylic acid; Et, ethionamide; M, moxifloxacin; Lv, levofloxacin; Cp, capreomycin; Ak, amikacin; O, ofloxacin; Rb, rifabutin; Z, pyrazinamide; LZD/L, linezolid; Cs, D-cycloserine; Pt, prothionamide; NA, not applicable). Strain lineage refers to the global phylogenetic group to which the strain belongs. b, MBC determination for linezolid and MK-7762 after 7 days of exposure of H37Rv to drug (two biological replicates shown in squares and circles). c, Sequence of Rv3160c in MK-7762-selected resistant mutants along with their cross-resistance to linezolid. d, Metabolite analysis of MK-7762 exposed to wild-type (WT) or mutant (A6) cells showing absorbance profiles at 270 nm and mass spectrometer determination of molecular weights (AMU) above select peaks (the same three mass profiles were seen in all but heat-killed organisms but not all peaks are labeled).